PDX Portal

Model Details

Patient Information for Model: BCM-7821

Model Contact

Model: BCM-7821
Model Contact: Michael Lewis
Institution: BCM Breast PDX Program
Email: mtlewis@bcm.edu

Patient Information

Clinical Timeline

Color Keys:

Positive

Negative

N/A

Clinical Information at Collection

Clinical Biomarkers/Mutations at Collection

Pathology Information at Collection

Model Information for Model: BCM-7821

Model Details - Initial Implantation of Patient Tissue

Biomarkers & Mutations

Model Details - Acceptable Conditions for Passaging

Mutations (Cancer Gene Census List)

GeneFilter by Gene	ChrFilter by Chr	Start	End	Ref	Alt	cDNA Change	Codon Change	Protein Change	TVAF	Gene Mutation Freq.	Site Mutation Freq.	Most Severe Effect	All Effects	Mutation Impact	Transcript ID	ClinVar Clinical Significance	COSMIC ID	gnomAD Non-Cancer AF	dbSNP ID	Gene Mutation Freq.	Site Mutation Freq.	Transcript ID	ClinVar Clinical Significance	COSMIC ID	dbSNP ID
AFF3	chr2	100104447	100104447	C	A	c.8G>T	aGc/aTc	p.S3I	0.5	56	1	Missense Variant	Missense Variant	MODERATE	ENST00000409579.5				.	56	1	ENST00000409579.5			.
AFF4	chr5	132896456	132896456	C	G	c.2174G>C	aGa/aCa	p.R725T	0.967	20	1	Missense Variant	Missense Variant	MODERATE	ENST00000265343.10			0.000126696000	rs138811630	20	1	ENST00000265343.10			rs138811630
AKAP9	chr7	92022864	92022864	A	AAAC	c.4004_4006dup	aaa/aAACaa	p.K1335_L1336insQ	0.998	115	73	In-frame Insertion	In-frame Insertion	MODERATE	ENST00000356239.8		COSV62337888		rs10644111	115	73	ENST00000356239.8		COSV62337888	rs10644111
AKAP9	chr7	92001306	92001306	G	T	c.1389G>T	atG/atT	p.M463I	0.941	115	73	Missense Variant	Missense Variant	MODERATE	ENST00000356239.8	Benign	COSV62345589	0.376835000000	rs6964587	115	73	ENST00000356239.8	Benign	COSV62345589	rs6964587
AKAP9	chr7	92097290	92097290	A	G	c.10331A>G	cAg/cGg	p.Q3444R	0.924	115	2	Missense Variant	Missense Variant	MODERATE	ENST00000356239.8	Benign/Likely_benign		0.003692220000	rs34956633	115	2	ENST00000356239.8	Benign/Likely_benign		rs34956633
AKAP9	chr7	92085597	92085597	C	T	c.8935C>T	Cct/Tct	p.P2979S	0.998	115	115	Missense Variant	Missense Variant	MODERATE	ENST00000356239.8	Benign/Likely_benign	COSV104663065	0.996325000000	rs1063242	115	115	ENST00000356239.8	Benign/Likely_benign	COSV104663065	rs1063242
AKAP9	chr7	92029945	92029945	T	C	c.4199T>C	aTg/aCg	p.M1400T	0.057	115	9	Missense Variant	Missense Variant	MODERATE	ENST00000356239.8	Benign/Likely_benign		0.012255900000	rs73407505	115	9	ENST00000356239.8	Benign/Likely_benign		rs73407505
ALK	chr2	29193706	29193706	T	C	c.4381A>G	Atc/Gtc	p.I1461V	0.995	115	115	Missense Variant	Missense Variant	MODERATE	ENST00000389048.8	Benign	COSV101201052	0.997594000000	rs1670283	115	115	ENST00000389048.8	Benign	COSV101201052	rs1670283
ALK	chr2	29193615	29193615	T	C	c.4472A>G	aAg/aGg	p.K1491R	0.549	115	51	Missense Variant	Missense Variant	MODERATE	ENST00000389048.8	Benign	COSV66555753	0.349007000000	rs1881420	115	51	ENST00000389048.8	Benign	COSV66555753	rs1881420
ALK	chr2	29193500	29193500	G	C	c.4587C>G	gaC/gaG	p.D1529E	0.435	115	80	Missense Variant	Missense Variant	MODERATE	ENST00000389048.8	Benign	COSV66569695	0.472160000000	rs1881421	115	80	ENST00000389048.8	Benign	COSV66569695	rs1881421
AMER1	chrX	64192810	64192810	A	C	c.477T>G	ttT/ttG	p.F159L	0.98	23	16	Missense Variant	Missense Variant	MODERATE	ENST00000374869.8	Benign	COSV57654201	0.041796500000	rs34677493	23	16	ENST00000374869.8	Benign	COSV57654201	rs34677493
APC	chr5	112841059	112841059	T	A	c.5465T>A	gTc/gAc	p.V1822D	0.97	100	100	Missense Variant	Missense Variant	MODERATE	ENST00000257430.9	Benign	COSV57321643	0.794920000000	rs459552	100	100	ENST00000257430.9	Benign	COSV57321643	rs459552
AR	chrX	67545316	67545319	TGCA	T	c.237_239del	ctGCAg/ctg	p.Q80del	0.915	101	35	In-frame Deletion	In-frame Deletion	MODERATE	ENST00000374690.9		COSV65954886		.	101	35	ENST00000374690.9		COSV65954886	.
ARID1A	chr1	26696516	26696516	A	AGGC	c.126_128dup	gag/gaGGCg	p.A45dup	0.736	48	3	In-frame Insertion	In-frame Insertion	MODERATE	ENST00000324856.13		COSV61373740		.	48	3	ENST00000324856.13		COSV61373740	.
ARID1B	chr6	157148881	157148881	A	G	c.3019A>G	Act/Gct	p.T1007A	0.549	80	1	Missense Variant	Missense Variant	MODERATE	ENST00000636930.2		COSV104575404	0.000004249320	rs1442559706	80	1	ENST00000636930.2		COSV104575404	rs1442559706

CNV

PDX Validation

In order to validate the identity of Baylor College of Medicine patient-derived xenograft (PDX) models, short tandem repeat (STR) testing is performed at the Cytogenetics and Cell Authentication core facility at MDACC. STR testing is performed on tissue from the initial tumor grown in the mouse (transplant generation 1 - TG1) and from a patient sample when possible. Thereafter, STR testing is performed every five transplant generations (TG5, TG10, TG15, and TG20). In the case that a PDX model is transplanted from viably frozen tissue to restart the model, the PDX Core will test the first outgrowth to confirm identity and every five transplant generations thereafter. In addition to STR, we assess clinical biomarkers and histology every 5th transplant generation. Finally, RNAseq gene expression profiles are evaluated periodically to ensure consistency with previous results and to evaluate phenotypic drift. If a significant change in PDX biology is noted, we identify the last known stable stock and re-start the model.

Drug Studies for Model: BCM-7821

Treatment Response Across All Studies

CR <=-95% to -100% PR <-30% to >-95% SD >=-30% to +20% PD >=+20% NA

Drug Study: VFoundation

Study Metadata

Study ID: VFoundation
Study Type: Efficacy
Study Description:
Dosing Initiation Timepoint: Randomization and treatment began after average tumor size in cohort reached 150 mm³
Number of Arms: 10
Mouse Strain:

PI: Mike Lewis
Study Title: VFoundation Study
Treatments: AC, AC+C188-9, C188-9, Carbo, Carbo+C188-9, Doc20, Doc20+C188-9, Pac, Pac+C188-9
Study Duration:
Transplant Site
Transplant Material:

Study Design

Arm Type	Treatment Arms	Number of Mice
Treatment	Docetaxel20+C188-9	6
Treatment	C188-9	6
Treatment	AC	6
Treatment	Docetaxel20	6
Treatment	Carboplatin	6
Control	Vehicle
Treatment	Carboplatin+C188-9	6
Treatment	AC+C188-9	5

Treatment Results

Treatment Arm	Treatment Duration	Monitor Duration	Tumor volume over time (%)	Response Category
Docetaxel20+C188-9	28	28	5	SD
C188-9	28	28	205	PD
AC	28	28	33	PD
Docetaxel20	28	28	9	SD
Carboplatin	28	28	157	PD
Vehicle	28	28	262	PD
Carboplatin+C188-9	28	28	107	PD
AC+C188-9	28	28	30	PD

Histology Information for Model: BCM-7821

There are no histology images for this model.

Metastasis Information for Model: BCM-7821

Patient

PDX

Abdomen

Adrenal gland

Bone

Bone (de novo)

Bones

Brain

CTC

Chest

Chest wall

Contralateral Breast

Dura

Fallopian Tubes

Head

Kidney

LMD

Liver

Lung

Lymph node

Lymph nodes

Neck

None

Ovary

Pancreas

Pericardium

Peritoneal cavity

Peritoneum

Pleura

Pleural effusion

Shoulder

Skin

Spine

Spleen

Thoracic Spine

Thymus

medistinal and right hilar

Patient Treatment Information for Model: BCM-7821

Event Id	Treatment	Treatment Setting	Age at Start	Age at End	Duration	Clinical Response	Pathologic Response	Reason Stopped
20	Docetaxel	Neoadjuvant	49.79	49.96	62 days	Partial Response	Partial Response	Treatment Completed
35	Cyclophosphamide,Epirubicin	Adjuvant	50.11	50.3	69 days	Not Reported	Not Applicable	Treatment Completed
40	Radiation Therapy	Adjuvant	50.37	50.51	51 days	Not Reported	Not Applicable	Treatment Completed
55	Capecitabine,Ixabepilone	Metastatic	51.31	51.64	120 days	Partial Response	Not Applicable	Treatment Completed
60	Radiation Therapy	Metastatic	51.77	51.83	22 days	Not Reported	Not Applicable	Treatment Completed
70	Paclitaxel	Metastatic	52.62	52.73	40 days	Disease Progression	Not Applicable	Side Effects
80	Carboplatin	Metastatic	52.82	52.86	15 days	Disease Progression	Not Applicable	Disease Progression